Biotech Values

[genisi]

Gilead Finalizes Selection of Bioequivalent Formulation for the Fixed-Dose Regimen of Truvada® and Tibotec Pharmaceuticals' TMC278

http://finance.yahoo.com/news/Gilead-Finalizes-Selection-of-bw-3098125952.html?x=0&.v=1


Gilead Sciences, Inc. (Nasdaq:GILD - News) announced today it has obtained data supporting bioequivalence of a formulation of the fixed-dose combination of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals’ investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride, 25 mg). A bioequivalence study is required to demonstrate that a co-formulated product results in the same levels of medication in the blood as achieved when the individual products are dosed simultaneously as separate pills. Gilead anticipates submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the fixed-dose combination following validation of the TMC278 NDA.